Chemotherapy-induced peripheral neuropathy (CIPN) refers to numbness, tingling, and burning sensation caused by chemotherapy that can cause impairment in Quality of Life (QoL) of the patients. Study assesses severity, risk factors, and quality of life of patients associated with CIPN. A cross sectional descriptive study was conducted at day care ward, tertiary care hospital India. Total of 98 patients receiving paclitaxel for ≥4 months were enrolled by convenient sampling. Data regarding demographics and clinical characteristics, CIPN severity, risk factors, and QoL were collected by structured questionnaires. Study revealed that median score of autonomic symptoms was higher than sensory and motor symptoms. Mean score of FACT/GOG-Ntx sub-domain was 99.05 ± 20.87on a scale of 0 to 152. ECOG Performance status, current exercise behavior, and fruit and vegetable intake was found to be significantly (at p < .05) associated with sensory, motor, and autonomic symptom score. Therefore, CIPN was found to have debilitating effect on QoL.
ChengH. L.LopezV.LamS. C.LeungA. K.LiY. C.WongK. H.AuJ. S.SundarR.ChanA.De NgT. R.SuenL. K.ChanC. W.YorkeJ.MolassiotisA. (2020). Psychometric testing of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group—Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy. Health and Quality of Life Outcomes, 18, 246. https://doi.org/10.1186/s12955-020-01493-y
3.
DerksenT. M.BoursM. J.MolsF.WeijenbergM. P. (2017). Lifestyle-related factors in the self-management of chemotherapy-induced peripheral neuropathy in colorectal cancer: A systematic review. Evidence-based Complementary and Alternative Medicine, 2017, 7916031. https://doi.org/10.1155/2017/7916031
4.
DhawanS.AndrewsR.KumarL.WadhwaS.ShuklaG. (2020). A randomized controlled trial to assess the effectiveness of muscle strengthening and balancing exercises on chemotherapy-induced peripheral neuropathic pain and quality of life among cancer patients. Cancer Nursing, 43(4), 269–280. https://doi.org/10.1097/NCC.0000000000000693
5.
EganM.BurkeE.MeskellP.MacNeelaP.DowlingM. (2015). Quality of life and resilience related to chemotherapy-induced peripheral neuropathy in patients post treatment with platinums and taxanes. Journal of Research in Nursing, 20(5), 385–398. https://doi.org/10.1177/1744987115574296
GhoreishiZ.KeshavarzS.Asghari JafarabadiM.FathifarZ.GoodmanK. A.EsfahaniA. (2018). Risk factors for paclitaxel-induced peripheral neuropathy in patients with breast cancer. BMC Cancer, 18(1), 958. https://doi.org/10.1186/s12885-018-4869-5
8.
GordonB. S.GbadamosiB.JaiyesimiI. A. (2018). The relationship between chemotherapy-induced neuropathy and quality of life in breast cancer survivors. Journal of Clinical Oncology, 36(Suppl. 15), e22111–e22111. https://doi.org/10.1200/jco.2018.36.15_suppl.e22111
9.
GomesG. L. L.OliveiraF. M. R. L.BarbosaK. T. F.MedeirosA. C. T.FernadesM. G. M.NóbregaM. M. L. (2019). Theory of unpleasant symptoms: critical analysis. Texto Contexto Enferm [Internet], 28, e20170222. https://doi.org/10.1590/1980-265X-TCE-2017-0222
10.
GreenleeH.HershmanD. L.ShiZ.KwanM. L.ErgasI. J.RohJ. M.KushiL. H. (2017). BMI, lifestyle factors and taxane-induced neuropathy in breast cancer patients: The pathways study. Journal of the National Cancer Institute, 109(2), djw206.
11.
HongJ. S.TianJ.WuL. H. (2014). The influence of chemotherapy-induced neurotoxicity on psychological distress and sleep sisturbance in cancer patients. Current Oncology, 21(4), 174–180. https://doi.org/10.3747/co.21.1984
12.
KolbN.KarafiathS.VivancoF.SingletonJ. R.SmithA. G. (2019). The prevalence, severity and risk factors for chemotherapy induced peripheral neuropathy at 0 and 2 years after the completion of paclitaxel therapy (P2.4-012). Neurology, 92(Suppl. 15), P2.4-012.
13.
LenzE. R.PughL. C.MilliganR. A.GiftA.SuppeF. (1997). The middle-range theory of unpleasant symptoms: an update. ANS. Advances in Nursing Science, 19(3), 14–27. https://doi.org/10.1097/00012272-199703000-00003
14.
MandepudiA.PaibhaviP. R. M, M. K.MakaV. V.ReddyH. (2019). 448P - Incidence and severity of chemotherapy induced peripheral neuropathy in geriatric population who are receiving chemotherapy. Annals of Oncology, 30, ix148. https://doi.org/10.1093/annonc/mdz434.028
15.
MolassiotisA.ChengH. L.LeungK. T.LiY. C.WongK. H.AuJ. S. K.SundarR.ChanA.NgT. R.SuenL. K. P.ChanC. W.YorkeJ.LopezV. (2019). Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy. Brain and Behavior, 9(6), e01312. https://doi.org/10.1002/brb3.1312
16.
MolsF.BeijersT.VreugdenhilG.van de Poll-FranseL. (2014). Chemotherapy-induced peripheral neuropathy and its association with quality of life: A systematic review. Supportive Care in Cancer, 22, 2261–2269. https://doi.org/10.1007/s00520-014-2255-7
17.
PostmaT. J.AaronsonN. K.HeimansJ. J.MullerM. J.HildebrandJ. G.DelattreJ. Y.Hoang-XuanK.Lantéri-MinetM.GrantR.HuddartR.MoynihanC.MaherJ.LuceyR. (2005). The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. European Journal of Cancer, 41(8), 1135–1139. https://doi.org/10.1016/j.ejca.2005.02.012
18.
QuasthoffS.HartungH. P. (2002). Chemotherapy-induced peripheral neuropathy. Journal of Neurology, 249(1), 9–17. https://doi.org/10.1007/PL00007853
SchoutenS. M.van de VeldeM. E.KaspersG. J. L.MokkinkL. B.van der SluisI. M.van Den BosC.HartmanA.AbbinkF. C. H.van Den BergM. H. (2020). Measuring vincristine-induced peripheral neuropathy in children with cancer: Validation of the Dutch pediatric-modified total neuropathy score. Supportive Care in Cancer, 28(6), 2867–2873. https://doi.org/10.1007/s00520-019-05106-3
21.
SmithE. M. (2013). Current methods for the assessment and management of taxane-related neuropathy. Clinical Journal of Oncology Nursing, 17(Suppl), 22–34. https://doi.org/10.1188/13.CJON.S1.22-34
22.
StarobovaH.VetterI. (2017). Pathophysiology of chemotherapy-induced peripheral neuropathy. Frontiers in Molecular Neuroscience, 10, 174. https://doi.org/10.3389/fnmol.2017.00174
TofthagenC.McAllisterR. D.VisovskyC. (2013). Peripheral neuropathy caused by paclitaxel and docetaxel: An evaluation and comparison of symptoms. Journal of the Advanced Practitioner in Oncology, 4(4), 204–215.
25.
YangI.-S.KangY. (2018). Self-care model based on the theory of unpleasant symptoms in patients with heart failure. Applied Nursing Research, 43, 10–17. https://doi.org/10.1016/j.apnr.2018.06.005
26.
ZajączkowskaR.Kocot-KępskaM.LeppertW.WrzosekA.MikaJ.WordliczekJ. (2019). Mechanisms of chemotherapy-induced peripheral neuropathy. International Journal of Molecular Sciences, 20(6), 1451. https://doi.org/10.3390/ijms20061451
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
